keyword
MENU ▼
Read by QxMD icon Read
search

rituximab hepatitis b reactivation

keyword
https://www.readbyqxmd.com/read/28898281/randomized-prospective-study-evaluating-tenofovir-disoproxil-fumarate-prophylaxis-against-hepatitis-b-virus-reactivation-in-anti-hbc-positive-patients-with-rituximab-based-regimens-to-treat-hematologic-malignancies-the-preblin-study
#1
María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
BACKGROUND: Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. METHODS: PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain...
2017: PloS One
https://www.readbyqxmd.com/read/28856548/risk-of-hepatitis-b-reactivation-in-hbsag-negative-hbcab-positive-patients-with-undetectable-serum-hbv-dna-after-treatment-with-rituximab-for-lymphoma-a-meta-analysis
#2
Zilin Tang, Xiaodong Li, Shunquan Wu, Yan Liu, Yan Qiao, Dongping Xu, Jin Li
BACKGROUND: Hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (HBcAb)-positive patients with undetectable serum hepatitis B virus (HBV) DNA have experienced and resolved hepatitis B virus (HBV) infection. Lymphoma patients with resolved HBV infection have high risk of HBV reactivation when treated with robust immunosuppressive agents, but the reported rate varies extensively between different studies. This study aims to estimate the risk of HBV reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab-containing chemotherapy for lymphoma...
August 30, 2017: Hepatology International
https://www.readbyqxmd.com/read/28852481/infectious-complications-of-rituximab-therapy-in-renal-disease
#3
Andrew Nixon, Leanne Ogden, Alexander Woywodt, Ajay Dhaygude
Rituximab, an anti-CD20 monoclonal antibody, was originally used to treat B-cell malignancies. Its use has significantly increased in recent years, as it is now also used to treat a variety of autoimmune diseases including rheumatoid arthritis and ANCA-associated vasculitis (AAV). Initial studies suggested that the adverse effects of rituximab were minimal. Though the risk of malignancy with rituximab-based immunosuppressive regimens appears similar to that of the general population, there are now concerns regarding the risk of infectious complications...
August 2017: Clinical Kidney Journal
https://www.readbyqxmd.com/read/28838453/cholestasis-after-pediatric-liver-transplantation-recurrence-of-a-progressive-familial-intrahepatic-cholestasis-phenotype-as-a-rare-differential-diagnosis-a-case-report
#4
B Prusinskas, S Kathemann, D Pilic, B Hegen, P Küster, V Keitel, D Häussinger, R Büscher, H A Baba, P F Hoyer, E Lainka
INTRODUCTION: Nonobstructive cholestasis after pediatric liver transplantation is a common diagnostic and therapeutic dilemma. We describe a girl with neonatal cholestasis because of progressive familial intrahepatic cholestasis 2 (PFIC-2) and presence of a homozygous splice site mutation in the ABCB11 gene. Liver transplantation was performed because of end-stage liver disease at the age of 6. Cholestasis with normal gamma-glutamyl transferase (GGT) developed 8 years after liver transplantation...
September 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28768965/reactivation-of-occult-hepatitis-b-virus-infection-27-months-after-the-end-of-chemotherapy-including-rituximab-for-malignant-lymphoma
#5
Junichi Muraishi, Michihiko Shibata, Yuichi Honma, Masaaki Hiura, Shintaro Abe, Masaru Harada
A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28665891/incidence-of-hepatitis-b-viral-reactivation-after-kidney-transplantation-with-low-dose-rituximab-administration
#6
Kosuke Masutani, Kazuya Omoto, Masayoshi Okumi, Yasuhiro Okabe, Tomokazu Shimizu, Kazuhiko Tsuruya, Takanari Kitazono, Masafumi Nakamura, Hideki Ishida, Kazunari Tanabe
BACKGROUND: In hematological malignancy patients intended to receive rituximab, hepatitis B virus (HBV) serology screening, viral reactivation monitoring, are recommended. However, the effect of single-dose rituximab (RIT) on HBV reactivation in kidney transplant patients with previous HBV infection is still unclear. METHODS: In this retrospective cohort study consisting of 1294 kidney transplant patients, we identified 76 patients showing preoperative hepatitis B surface antigen-negative, hepatitis B core antibody-positive, and HBV-DNA negative results...
June 29, 2017: Transplantation
https://www.readbyqxmd.com/read/28648087/cost-effectiveness-of-a-hepatitis-b-virus-screening-strategy-to-prevent-reactivation-in-patients-with-hematologic-neoplasms
#7
Javier Crespo, Rafael Esteban, Covadonga Torres, Itziar Oyagüez, Miguel Ángel Casado, María Buti
INTRODUCTION: The effectiveness of a screening strategy for the detection of a hepatitis B virus (HBV) infection followed by prophylaxis in order to prevent HBV reactivation was assessed in patients with hematologic neoplasms. MATERIAL AND METHODS: A decision tree was developed to compare the cost and effectiveness (prevented reactivations) over an 18 month period of a screening strategy prior to chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) with a non-screening approach...
June 26, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28633752/rituximab-administration-in-a-patient-with-pemphigus-vulgaris-following-reactivation-of-occult-hepatitis-b-virus-infection
#8
Soheil Tavakolpour, Tahereh Soori, Pedram Noormohammadpour, Kamran Balighi, Hamidreza Mahmoudi, Maryam Daneshpazhooh
Immunosuppressive drugs are the milestone of treatment of autoimmune diseases, but they can lead to serious complications, including hepatitis B virus reactivation in HBV carriers as well as in patients with occult HBV infection (OBI). A 36-year-old man with OBI was diagnosed with pemphigus vulgaris. He was prescribed prednisolone and his hepatitis B surface antigen turned positive. Viral replication was successfully controlled by lamivudine and adefovir. Mycophenolate mofetil and intravenous immunoglobulin  were not effective in controlling the pemphigus vulgaris...
June 20, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28566622/factorial-analysis-of-hepatitis-b-virus-reactivation-induced-hepatitis-b-using-jader
#9
Ayako Hara, Kazuaki Matsumoto, Yuta Yokoyama, Junko Kizu
Hepatitis B caused by chemotherapy- and immunosuppression-associated hepatitis B virus reactivation is likely to become fulminant, and a high mortality rate has been reported. In this study, using the Japanese adverse drug event report database (JADER), factorial analysis of patients who developed hepatitis B as an adverse event was performed. The number of reported cases of hepatitis B during the survey period was 781 and 185 of them (24%) died. Rituximab and prednisolone were administered to many cases (233, 216 cases, respectively), and the reporting odds ratios were high (65...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28414152/rituximab-for-immunologic-renal-disease-what-the-nephrologist-needs-to-know
#10
REVIEW
Andreas Kronbichler, Martin Windpessl, Herwig Pieringer, David R W Jayne
Rituximab (RTX), a chimeric, monoclonal anti-CD20 antibody, is increasingly used in immune-mediated renal diseases. While licensed in the induction treatment of ANCA-associated vasculitis, it represents one of the most commonly prescribed off-label drugs. Much of the information regarding its safety has been drawn from experience in hematology and rheumatology. Ample evidence illustrates the safety of RTX, however, rare but serious adverse events have emerged that include progressive multifocal leucoencephalopathy and hepatitis B reactivation...
June 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28375829/incidence-and-clinical-characteristics-of-hepatitis-b-virus-reactivation-in-hbsag-negative-hbcab-positive-patients-receiving-rituximab-for-rheumatoid-arthritis
#11
Ya-Chih Tien, Hsu-Heng Yen, Ying-Ming Chiu
OBJECTIVES: To analyse the incidence, clinical characteristics, and prognosis of patients with rheumatoid arthritis (RA) and hepatitis B virus (HBV) surface antigen negative/core antibody positive serostatus (HBsAg-/HBcAb+), who underwent rituximab therapy and developed HBV reactivation. METHODS: Medical records of RA patients with different HBV serostatus who received rituximab from January 2000 through January 2015 were reviewed. Case notes of four HBsAg-/HBcAb+ patients with RA who had HBV reactivation during treatment with rituximab were excerpted and summarised...
March 31, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28353614/using-health-system-wide-data-to-understand-hepatitis-b-virus-prophylaxis-and-reactivation-outcomes-in-patients-receiving-rituximab
#12
Gabriela Schmajuk, Chris Tonner, Laura Trupin, Jing Li, Urmimala Sarkar, Dana Ludwig, Stephen Shiboski, Marina Sirota, R Adams Dudley, Sara Murray, Jinoos Yazdany
Hepatitis B virus (HBV) reactivation in the setting of rituximab use is a potentially fatal but preventable safety event. The rate of HBV screening and proportion of patients at risk who receive antiviral prophylaxis in patients initiating rituximab is unknown.We analyzed electronic health record (EHR) data from 2 health systems, a university center and a safety net health system, including diagnosis grouper codes, problem lists, medications, laboratory results, procedures codes, clinical encounter notes, and scanned documents...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28339910/rituximab-and-hepatitis-b-reactivation-in-hbsag-negative-anti-hbc-positive-kidney-transplant-recipients
#13
Juhan Lee, Jun Yong Park, Kyu Ha Huh, Beom Seok Kim, Myoung Soo Kim, Soon Il Kim, Sang Hoon Ahn, Yu Seun Kim
Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy. Although rituximab is increasingly used for desensitization of ABO-incompatible or positive crossmatch kidney transplantation, the risk of HBV reactivation in hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (anti-HBc)-positive kidney transplant patients receiving rituximab desensitization remains undetermined. Methods: We analysed 172 resolved HBV patients who underwent living donor kidney transplantation between 2008 and 2014...
April 1, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28140702/antiviral-therapies-for-managing-viral-hepatitis-in-lymphoma-patients
#14
REVIEW
Michele Merli, Sara Rattotti, Manuel Gotti, Luca Arcaini
In patients with lymphoma the detection of positive hepatitis B or C viruses (HBV and HCV) serology involves crucial therapeutic consequences. In HBV-infected patients the serological profile of active (HBsAg-positive) or resolved (HBsAg-negative/anti-HBcAb-positive) infection is associated to differential risk of viral reactivation during rituximab-based therapy and require appropriate strategies of monitoring and of antiviral prophylaxis. In HCV-associated NHL patients consolidated data demonstrated that interferon (IFN)-based antiviral therapy (AT) is able to induce lymphoma regression strictly related to viral eradication, while preliminary data of the new direct-acting antivirals (DAAs) are very promising...
March 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28128861/role-of-surface-antibody-in-hepatitis-b-reactivation-in-patients-with-resolved-infection-and-hematologic-malignancy-a-meta-analysis
#15
REVIEW
Sonali Paul, Aaron Dickstein, Akriti Saxena, Norma Terrin, Kathleen Viveiros, Ethan M Balk, John B Wong
Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation. Because of conflicting studies about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against reactivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hematological malignancies, we conducted a meta-analysis to determine if anti-HBs reduces HBV reactivation risk. We sought English-language studies through March 1, 2016, in Medline and other sources that examined reactivation in patients with resolved HBV infection receiving chemotherapy for hematologic malignancies...
August 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28011918/hepatitis-b-virus-reactivation-in-rheumatoid-arthritis-patients-undergoing-biologics-treatment
#16
Ming-Han Chen, Ming-Huang Chen, Chun-Yu Liu, Chang-Youh Tsai, De-Feng Huang, Hsiao-Yi Lin, Mei-Hsuan Lee, Yi-Hsiang Huang
Background: Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informative data about the risk of different immunosuppressive regimens, including biologics, on HBV reactivation (HBVr) among patients with rheumatoid arthritis (RA) are incomplete. Methods: Among 2334 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients positive for HBsAg who were not receiving anti-HBV prophylaxis were enrolled. These patients were undergoing varied mono or combination immunosuppressive therapy, including 36 who were receiving biological disease-modifying antirheumatic drugs (bDMARDs)...
February 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27747531/rituximab-for-rheumatoid-arthritis
#17
REVIEW
Marc D Cohen, Edward Keystone
Rituximab is a chimeric monoclonal antibody directed at the CD20 molecule on the surfaces of some but not all B cells. It depletes almost all peripheral B cells, but other niches of B cells are variably depleted, including synovium. Its mechanism of action in rheumatoid arthritis (RA) is only partially understood. Rituximab was efficacious in clinical trials of patients with RA, including those who are methotrexate naïve, those with an incomplete response to methotrexate, and those with an incomplete response to tumor necrosis factor inhibitors...
December 2015: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27743784/hepatitis-b-virus-reactivation-after-cessation-of-prophylaxis-with-entecavir-in-a-patient-with-burkitt-type-acute-lymphoblastic-leukaemia-treated-with-rituximab
#18
Alba Juan Juan, Noemi Caballero de García, Helena Masnou Ridaura, Marga Sala Llinas, M Rosa Morillas, Ramon Planas Vila
No abstract text is available yet for this article.
August 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/27708965/viral-hepatitis-screening-guideline-before-biological-drug-use-in-rheumatic-patients
#19
REVIEW
Ömer Karadağ, Timuçin Kaşifoğlu, Birol Özer, Sabahattin Kaymakoğlu, Yeşim Kuş, Murat İnanç, Gökhan Keser, Sedat Kiraz
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary...
March 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27696389/improvements-in-hepatitis-b-virus-screening-before-rituximab-therapy-a-community-based-safety-net-hospital-experience
#20
Kevin Junus, Maria Aguilar, Priya Patel, David Irwin, Stephen Yee, Benny Liu, Taft Bhuket, Robert J Wong
BACKGROUND: Individuals with chronic hepatitis B virus infection (HBV) or previously resolved HBV are at increased risk of HBV exacerbation or reactivation when they receive treatment with anti-CD20 monoclonal antibodies (against B-lymphocyte antigen cluster of differentiation 20 [CD20], an activated-glycosylated phosphoprotein) like rituximab (RTX). The objective of the current study was to evaluate the rates of appropriate HBV screening before patients started receiving RTX, at the initiation of HBV treatment, and during HBV flares among an underserved safety-net population...
February 15, 2017: Cancer
keyword
keyword
110035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"